See Pages 2, 3, 4

Form PTO-1449 (modified)		Temp. Atty. Docket No.	Serial No.	
		4001.003000	10/621,269	
List of Patents and Publications for	Applicant's	Applicant		
		Thorpe et al.		
INFORMATION DISCLOSURE STA	TEMENT			
		Filing Date:	Group:	
(Use several sheets if necess	sary)	July 15, 2003	1642	
U.S. Patent Documents Foreign Pa		atent Documents	Other Art	

See Page 2

See Page I

U.S. Patent Documents								
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.	
	A1	2002/0025319	Feb. 28, 2002	Brams	424	178.1		
	A2	2003/0004097	Jan. 02, 2003	Schroit	514	7		
	A3	2003/0228625	Dec. 11, 2003	Toh et al.	435	7.1		
	A4	2004/0175378	Sep. 09, 2004	Thorpe et al.	424	141.1		
	A5	2004/0208868	Oct. 21, 2004	Thorpe et al.	424	144.1		
	A6	2005/0002941	Jan. 06, 2005	Thorpe et al.	424	178.1		
	Α7	2005/0031620	Feb. 10, 2005	Thorpe et al.	424	155.1		
	A8	2005/0129696	Jun. 16, 2005	Thorpe et al.	424	155.1		
	A9	2005/0136059	Jun. 23, 2005	Thorpe et al.	424	155.1		
	A10	5,660,827	Aug. 26, 1997	Thorpe et al.	424	152.1		
	A11	5,677,171	Oct. 14, 1997	Hudziak et al.	435	7.23		
	A12	5,863,538	Jan. 26, 1999	Thorpe et al.	424	136.1		
	A13	6,300,308	Oct. 09, 2001	Schroit	514	8		
	A14	6,312,694	Nov. 06, 2001	Thorpe et al.	424	178.1		
	A15	6,333,348	Dec. 25, 2001	Vogel et al.	514	449		
	A16	6,406,693	Jun. 18. 2002	Thorpe et al.	424	130.1		
	A17	6,783,760	Aug. 31, 2004	Thorpc et al.	424	178.1		
	A18	6,806,354	Oct. 19, 2004	Schroit	530	387.1		
	A19	6,818,213	Nov. 16, 2004	Thorpc et al.	424	130.1		
	A20	7,067,109	Jun. 27, 2006	Thorpe et al.	424	1.49		

EXAMINER:

DATE CONSIDERED:

EXAMINER INITIAL E REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONSIDERANCE WITH MPEP699, DRAW LINE THROUGH CITATION IS

NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

Form PTO-1449 (modified)		Temp. Atty. Docket No. Serial No.			
		4001.003000		10/621,269	
List of Patents and Publications for	Applicant's	Applicant			
INFORMATION DISCLOSURE STATEMENT		Thorpe et al.			
		Filing Date:		Group:	
(Use several sheets if necessar	7)	July 15, 2003		1642	
T. C. Dataset Danson and	P'- D	-tt D		Ost 1-4	

U.S. Patent Documents Foreign Patent Documents Other Art
See Page 1 See Page 2 See Page 2, 3, 4

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 00/02584	Jan. 20, 2000	PCT			
	B2	WO 00/02587	Jan. 20, 2000	PCT			
	B3	WO 01/03735	Jan. 18, 2001	PCT			
	B4	WO 01/68709	Sep. 20, 2001	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

water rat (moraling reason; rate; sate r criment r ages; stor)								
Exam. Init.	Ref. Des.	Citation						
	Cı	Balasubramanian and Schroit, "Aminophospholipid Asymmetry: A Matter of Life and Death", Annu. Rev. Physiol., 65:701-734, 2003.						
	C2	Beck et al., "Combination of a Monoclonal Anti-Phosphatidylserine Antibody with Gemeitabine Strongly Inhibits the Growth and Metastasis of Orthotopic Pancreatic Tumors in Mice," Int. J. Cancer, 118:2639-2643, 2006.						
	C3	lowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amnio Acid abstitutions", Science, 147:1306-1310, 1990.						
	C4	Goren et al., "Targeting of Stealth Liposomes in crbB-2 (HER/2) Receptor: In Vitro and In Vivo Studies", Brit. J. Cancer, 74:1749-1756, 1996.						
	C5	Güssow and Seemann, "Humanization of Monoclonal Antibodies", Methods in Enzymology, 203:99-121, 1991.						
	C6	Herbert et al., Eds., Dictionary of Immunology, 4th ed. London: Academic Press, 1995.						
	C7	Huang et al., "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docctaxel on Human Breast Tumors in Mice", Cancer Res., 65(10):4108-4116, 2005.						
	C8	Ishida et al., A Combinatorial Approach to Producing Sterically Stabilized (Stealth) Immunoliposomal Drugs", FEBS Letters, 460:129-133, 1999.						

EXAMINER:

DATE CONSIDERED:

EXAMINER INITIAL BY REPRENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IP NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH INEXT COMMUNICATION TO APPLICANT

					5 01 4
Form PTO-1449 (modified)		Temp. Atty. Docket No. Serial No.		Serial No.	
		4001.003000		10/621,269	
List of Patents and Publications for	Applicant's	Applicant			
INFORMATION DISCLOSURE ST	Thorpe et al.				
INFORMATION DISCLOSURE ST	ATEMENT				
		Filing Date:		Group:	
(Use several sheets if necessary)		July 15, 2003		1642	
U.S. Patent Documents	Foreign P	atent Documents		Other Art	
See Page 1	Se	See Page 2		See Pages 2, 3, 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam.	Ref. Des.	Citation
init.	Des.	
	C9	Janeway et al., "The Interaction of the Antibody Molecule with Specific Antigen", Immunobiology, 5th ed., 7 pages, 2001.
	C10	Lewis et al., "Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies", Cancer Immunol. Immunother., 37:255-263, 1993.
	C11	Luster et al., "Plasma Protein Beta-2-glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Annie Phospholipids on Endothelial Cells, JBC Papers in Press, www.ybc.org/egi/doi/10.1074/pb., M605252200:1-20, 2006.
	C12	Maruyama et al., "Lipid Composition is Important for Highly Efficient Target Binding and Retention of Immunoliposomes", Proc. Natl. Acad. Sci. USA, 87:5744-5748, 1990.
	C13	Ran and Thorpe, "Phosphatidylserine is a Marker of Tumor Vasculature and a Potential Target for Cancer Imaging and Therapy", Int. J. Radiation Oncology Biol. Phys., 54(5):1479-1484, 2002.
	C14	Ran et al., "Increased Exposure of Anionic Phospholipids on the Surface of the Tumor Blood Vessels", Cancer Res.; 62:6132-6140, 2002.
	C15	Ran et al., "Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice", Clin. Cancer Res., 11:1551-1562, 2005.
	C16	Rudikoff, "Single Amino Acid Substitution Altering Antigen-Binding Specificity", Proc. Natl. Acad. Sci. USA, 79:1979-1983, 1982.
	C17	Schneider-Gadicke and Riethmfiller, "Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Turnours", Eur. J. Cancer, 31A(78):1326-1330, 1995.
	C18	Stancovski et al., "Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth", Proc. Natl. Acad. Sci. USA, 88:8691-8695, 1991.
	C19	Strobel and Cannistra, "β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro", Gynecologic Oncology, 73:362-367, 1999.
	C20	Thorpe et al., "Tumor Infarction: Immunoconjugates that Coagulate the Vasculature of Solid Tumors", Proceeding of the American Association for Cancer Research, 36:488, Abstract #2910, March 1995.

EXAMINER:

DATE CONSIDERED:

EXAMINER INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT

						4 of 4
Form PTO-1449 (modified)			Temp. Atty. Docket N	Ño.	Serial No.	
		,		4001.003000		10/621,269
List of Pa	tents and	d Publications for	Applicant's	Applicant		
Information Disclosure Statement (Use several sheets if necessary)			Thorpe et al.			
			Filing Date: July 15, 2003		Group: 1642	
TLS.	Patent	Documents	Foreign P	atent Documents		Other Art
			ee Page 2		See Pages 2, 3, 4	
						•
		Other Art (Including Auth	nor, Title, Date Pertin	ent Pa	ges, Etc.)
Exam. Init.	Ref. Des.			Citation		
	C21	Contractual Euro March 31, 2004.	opean Search Ro	eport for counterpart Po	СТ Арр	dication, PCT/US03/21925, maile
	C22	European Search	Report for Coun	terpart European Applic	ation N	o. 03764600.7, dated Dec. 27, 2004
	C23	International Search Report for counterpart PCT Application, PCT/US03/21925, mailed F 2005.				PCT/US03/21925, mailed Feb. 24
	-					
	-					
	_					
	\vdash					
EXAMIN	ER:			DATE CONSIDE	RED:	